



GLAXOSMITHKLINE CONSUMER NIGERIA PLC

ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 30TH SEPTEMBER, 2014

GlaxoSmithKline Consumer Nigeria Plc
Statement of comprehensive income
For the period ended 30 September 2014

		GROUP			COMPANY		
		Nine months ended 30 September 2014	31 December 2013 N'000	Nine months ended 30 September 2013 N'000	Nine months ended 30 September 2014	31 December 2013 N'000	Nine months ended 30 September N'000
	Note						
Revenue		23,211,782	29,183,675	21,332,244	23,211,782	29,183,675	21,332,244
Cost of sales	6	(15,329,314)	(17,581,625)	(12,921,470)	(15,329,314)	(17,581,625)	(12,921,470)
Gross profit		7,882,469	11,602,050	8,410,774	7,882,469	11,602,050	8,410,774
Other operating income	5	193,185	82,460	22,066	193,185	79,207	22,066
Selling and distribution costs	6	(4,494,875)	(5,338,249)	(4,026,302)	(4,494,875)	(5,338,249)	(4,026,302)
Administrative expenses	6	(1,430,100)	(2,086,869)	(1,676,828)	(1,426,455)	(2,082,908)	(1,676,828)
Other operating expenses	7	(199,742)	(104,450)	(24,481)	(200,220)	(104,860)	(24,481)
Operating profit		1,950,936	4,154,942	2,705,229	1,954,104	4,155,240	2,705,229
Finance costs	8	(3,255)	(514)	(356)	(3,255)	(514)	(356)
Finance income	9	114,142	160,401	76,506	107,169	156,829	76,506
Profit before tax		2,061,823	4,314,829	2,781,379	2,058,018	4,311,555	2,781,379
Income tax expense	12	(579,597)	(1,395,659)	(849,227)	(579,597)	(1,395,659)	(849,227)
Profit for the year		1,482,226	2,919,170	1,932,152	1,478,421	2,915,896	1,932,152
Other comprehensive income:							
Items that will not be reclassified to profit or loss:							
Remeasurements on post employment benefit obligations	21		10,280			10,280	
Income tax effect	12		(3,084)			(3,084)	
Other comprehensive income for the year, net of tax			7,196			7,196	
Total comprehensive income for the year, net of tax		1,482,226	2,926,366	1,932,152	1,478,421	2,923,092	1,932,152
Earnings per share (Kobo)							
Basic and diluted, profit for the year attributable to ordinary equity holders of the parent	13		305			305	

GlaxoSmithKline Consumer Nigeria Plc
Statement of financial position
For the period ended 30 Septemeber 2014

		GROUP				COMPANY	
	Note	Nine months ended 30 September 2014 N'000	31 December 2013 N'000	Nine months ended 30 September 2013 N'000	Nine months ended 30 September 2014 N'000	31 December 2013 N'000	Nine months ended 30 September 2013 N'000
Assets							
Non-current assets							
Property, plant and equipment	14	12,752,945	12,121,857	11,188,674	12,752,945	12,121,857	11,188,674
Investment in subsidiary	15	-	-	-	160	160	160
		<u>12,752,945</u>	<u>12,121,857</u>	<u>11,188,674</u>	<u>12,753,105</u>	<u>12,122,017</u>	<u>11,188,834</u>
Current assets							
Inventories	16	6,630,569	5,616,340	5,544,456	6,630,569	5,616,340	5,544,456
Trade and other receivables	17	7,239,743	4,054,910	4,700,415	7,239,944	4,088,284	4,742,633
Prepayments	17	771,939	502,901	477,545	781,307	496,310	470,491
Cash and short- term deposits	18	1,632,345	3,917,655	2,790,164	1,433,555	3,699,202	2,580,421
		<u>16,274,595</u>	<u>14,091,806</u>	<u>13,512,581</u>	<u>16,085,374</u>	<u>13,900,136</u>	<u>13,338,001</u>
Total assets		<u>29,027,540</u>	<u>26,213,663</u>	<u>24,701,254</u>	<u>28,838,479</u>	<u>26,022,153</u>	<u>24,526,835</u>
Equity and liabilities							
Equity							
Issued share capital	19	478,351	478,351	478,351	478,351	478,351	478,351
Share premium	19	51,395	51,395	51,395	51,395	51,395	51,395
Retained earnings		<u>12,054,482</u>	<u>11,815,968</u>	<u>10,821,755</u>	<u>11,886,970</u>	<u>11,652,261</u>	<u>10,661,322</u>
Total equity		<u>12,584,229</u>	<u>12,345,714</u>	<u>11,351,501</u>	<u>12,416,716</u>	<u>12,182,007</u>	<u>11,191,068</u>
Non-current liabilities							
Employee benefit liability	21	150,216	136,109	145,635	150,216	136,109	145,635
Deferred tax liability	12	<u>1,950,422</u>	<u>1,950,422</u>	<u>1,490,927</u>	<u>1,950,421</u>	<u>1,950,422</u>	<u>1,490,927</u>
		<u>2,100,638</u>	<u>2,086,531</u>	<u>1,636,562</u>	<u>2,100,637</u>	<u>2,086,531</u>	<u>1,636,562</u>
Current liabilities							
Trade and other payables	22	13,593,348	10,789,451	10,818,977	13,590,809	10,780,658	10,816,269
Income tax payable	12	<u>749,326</u>	<u>991,967</u>	<u>894,215</u>	<u>730,315</u>	<u>972,957</u>	<u>882,936</u>
		<u>14,342,675</u>	<u>11,781,418</u>	<u>11,713,192</u>	<u>14,321,125</u>	<u>11,753,615</u>	<u>11,699,205</u>
Total liabilities		<u>16,443,313</u>	<u>13,867,949</u>	<u>13,349,754</u>	<u>16,421,762</u>	<u>13,840,146</u>	<u>13,335,767</u>
Total equity and liabilities		<u>29,027,540</u>	<u>26,213,663</u>	<u>24,701,254</u>	<u>28,838,478</u>	<u>26,022,153</u>	<u>24,526,835</u>

GlaxoSmithKline Consumer Nigeria Plc
Consolidated statement of changes in equity
For the period ended 30 September 2014

For the Nine months ended 30 September, 2014	Note	Issued share capital N'000	Share premium N'000	Retained earnings N'000	Total equity N'000
At 1 January 2014	19	478,351	51,395	11,815,967	12,345,714
Profit for the year				1,482,226	1,482,226
Other comprehensive income				-	-
		478,351	51,395	13,298,194	13,827,940
Dividend	20			(1,243,712)	(1,243,712)
At 30 September 2014		478,351	51,395	12,054,482	12,584,228

For the year ended 31 December, 2013	Note	Issued share capital N'000	Share premium N'000	Retained earnings N'000	Total equity N'000
At 1 January 2013	19	478,351	51,395	10,133,314	10,663,060
Profit for the year		-	-	2,919,170	2,919,170
Other comprehensive income		-	-	7,196	7,196
		478,351	51,395	13,059,680	13,589,426
Dividend	20	-	-	(1,243,712)	(1,243,712)
At 31 December 2013		478,351	51,395	11,815,967	12,345,714

For the Nine months ended 30 September, 2013		Issued share capital N'000	Share premium N'000	Retained earnings N'000	Total equity N'000
At 1 January 2013	19	478,351	51,395	10,133,314	10,663,060
Profit for the year				1,932,152	1,932,152
Other comprehensive income				-	-
		478,351	51,395	12,065,466	12,595,212
Dividend	20			(1,243,712)	(1,243,712)
Unclaimed dividend now statute barred					-
At 30 September 2013		478,351	51,395	10,821,754	11,351,500

GlaxoSmithKline Consumer Nigeria Plc
Financial Statements
For the period ended 30 September 2014

Company statement of changes in equity

For the Nine months ended 30 September, 2014	Note	Issued share capital N'000	Share premium N'000	Retained earnings N'000	Total equity N'000
At 1 January 2014	19	478,351	51,395	11,652,261	12,182,007
Profit for the year				1,478,421	1,478,421
Other comprehensive income					-
		<u>478,351</u>	<u>51,395</u>	<u>13,130,682</u>	<u>13,660,428</u>
Dividend	20			(1,243,712)	(1,243,712)
At 30 September 2014		<u>478,351</u>	<u>51,395</u>	<u>11,886,970</u>	<u>12,416,716</u>

For the year ended 31 December, 2013	Note	Issued share capital N000	Share premium N000	Retained Earnings N000	Total equity N000
As at 1 January 2013	19	478,351	51,395	9,972,881	10,502,627
Profit for the year		-	-	2,915,896	2,915,896
Other comprehensive income		-	-	7,196	7,196
		<u>478,351</u>	<u>51,395</u>	<u>12,895,974</u>	<u>13,425,719</u>
Dividend	20	-	-	(1,243,712)	(1,243,712)
At 31 December 2013		<u>478,351</u>	<u>51,395</u>	<u>11,652,261</u>	<u>12,182,007</u>

For the Nine months ended 30 September, 2013		Issued share capital N000	Share premium N000	Retained Earnings N000	Total equity N000
As at 1 January 2013	19	478,351	51,395	9,972,881	10,502,627
Profit for the year		-	-	1,932,152	1,932,152
Other comprehensive income		-	-		-
		<u>478,351</u>	<u>51,395</u>	<u>11,905,034</u>	<u>12,434,780</u>
Dividend	20	-	-	(1,243,712)	(1,243,712)
At 30 September 2013		<u>478,351</u>	<u>51,395</u>	<u>10,661,322</u>	<u>11,191,068</u>

GlaxoSmithKline Consumer Nigeria Plc
Statement of cash flows
For the period ended 30 September 2014

		GROUP			COMPANY		
	Note	Nine months ended 30 September 2014	31 December 2013 N'000	Nine months ended 30 September 2013 N'000	Nine months ended 30 September 2014	31 December 2013 N'000	Nine months ended 30 September 2013 N'000
Operating activities							
Profit before tax		2,061,823	4,314,829	2,781,379	2,058,018	4,311,555	2,781,379
Non-cash adjustment to reconcile profit before tax to net cash flows							
Depreciation of property, plant and equipment	14	859,575	926,035	617,338	859,575	926,036	617,338
Gain on disposal of property, plant and equipment	5	(6,987)	(12,590)	(7,190)	(6,987)	(12,590)	(7,190)
Finance income	9	(45,750)	(137,305)	(58,766)	(38,777)	(133,734)	(58,766)
Exchange (gain)/loss	5,7	76,604	(40,499)	(7,106)	76,604	(40,499)	(7,106)
Finance costs	8	3,255	514	356	3,255	514	356
Net charge on defined benefit obligations	21	14,107	27,820	17,473	14,107	27,820	17,473
Impairment / (net recovery) of trade receivables	17	75,461	45,608	18,958	75,461	46,018	18,958
Working capital adjustments:							
(Increase)/decrease in inventories		(1,014,229)	(1,061,037)	(989,154)	(1,014,229)	(1,107,536)	(1,035,652)
Increase in trade receivables		(3,260,294)	(602,445)	(1,221,300)	(3,227,121)	(441,625)	(1,068,914)
Decrease/(increase) in prepayments		(269,037)	35,399	60,755	(284,996)	41,421	67,242
Increase in trade and other payables		<u>2,727,292</u>	<u>2,515,944</u>	<u>2,528,637</u>	<u>2,733,547</u>	<u>2,516,848</u>	<u>2,535,628</u>
		1,221,824	6,012,274	3,741,380	1,248,458	6,134,228	3,860,745
Defined benefit obligation paid	21	-	(9,593)	0	-	(9,593)	-
Interest paid	8	(3,255)	(514)	(356)	(3,255)	(514)	(356)
Income tax paid		<u>(822,239)</u>	<u>(1,160,408)</u>	<u>(1,168,139)</u>	<u>(822,239)</u>	<u>(1,128,095)</u>	<u>(1,128,096)</u>
Net cash flows from operating activities		<u>396,329</u>	<u>4,841,758</u>	<u>2,572,885</u>	<u>422,964</u>	<u>4,996,026</u>	<u>2,732,294</u>
Investing activities							
Proceed from sale of property, plant and equipment		32,521	33,192	11,905	32,521	33,192	11,905
Interest received	9	45,750	137,305	58,766	38,777	133,734	58,766
Purchase of property, plant and equipment	14	<u>(1,516,197)</u>	<u>(4,233,435)</u>	<u>(2,975,666)</u>	<u>(1,516,197)</u>	<u>(4,233,435)</u>	<u>(2,975,666)</u>
Net cash flows used in investing activities		<u>(1,437,927)</u>	<u>(4,062,938)</u>	<u>(2,904,995)</u>	<u>(1,444,899)</u>	<u>(4,066,509)</u>	<u>(2,904,995)</u>
Financing activities							
Dividends paid to equity holders of the parent	20	<u>(1,243,712)</u>	<u>(1,243,712)</u>	<u>(1,243,712)</u>	<u>(1,243,712)</u>	<u>(1,243,712)</u>	<u>(1,243,712)</u>
Net cash flows used in financing activities		<u>(1,243,712)</u>	<u>(1,243,712)</u>	<u>(1,243,712)</u>	<u>(1,243,712)</u>	<u>(1,243,712)</u>	<u>(1,243,712)</u>
Net increase in cash and cash equivalents		(2,285,310)	(464,892)	(1,575,822)	(2,265,648)	(314,196)	(1,416,413)
Cash and cash equivalents at 1 January		3,917,655	4,365,986	4,365,986	3,699,202	3,996,835	3,996,834
Exchange gain / (loss) on cash and cash equivalents			<u>16,561</u>			<u>16,561</u>	
Cash and cash equivalents at the end of the period	18	<u>1,632,345</u>	<u>3,917,655</u>	<u>2,790,164</u>	<u>1,433,555</u>	<u>3,699,202</u>	<u>2,580,421</u>